These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
942 related articles for article (PubMed ID: 32022742)
1. Treatment of multidrug-resistant Gram-negative skin and soft tissue infections. Jabbour JF; Sharara SL; Kanj SS Curr Opin Infect Dis; 2020 Apr; 33(2):146-154. PubMed ID: 32022742 [TBL] [Abstract][Full Text] [Related]
2. The role of carbapenem-resistant pathogens in cSSTI and how to manage them. Del Giacomo P; Losito AR; Tumbarello M Curr Opin Infect Dis; 2019 Apr; 32(2):113-122. PubMed ID: 30648994 [TBL] [Abstract][Full Text] [Related]
3. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of ceftazidime-avibactam against gram-negative bacteria in patients with bacteremia and skin and soft-tissue infections in Colombia 2019-2021. Lemos-Luengas EV; Rentería-Valoyes S; Muñoz DMA; Gonzalez CKG; Guerrón-Gómez G; Ramos-Castaneda JA Diagn Microbiol Infect Dis; 2024 Jun; 109(2):116235. PubMed ID: 38458096 [TBL] [Abstract][Full Text] [Related]
5. New perspectives in the antibiotic treatment of mechanically ventilated patients with infections from Gram-negatives. Karvouniaris M; Pontikis K; Nitsotolis T; Poulakou G Expert Rev Anti Infect Ther; 2021 Jul; 19(7):825-844. PubMed ID: 33270485 [No Abstract] [Full Text] [Related]
6. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Cruz-López F; Martínez-Meléndez A; Morfin-Otero R; Rodriguez-Noriega E; Maldonado-Garza HJ; Garza-González E Front Cell Infect Microbiol; 2022; 12():884365. PubMed ID: 35669117 [TBL] [Abstract][Full Text] [Related]
8. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Wright H; Bonomo RA; Paterson DL Clin Microbiol Infect; 2017 Oct; 23(10):704-712. PubMed ID: 28893690 [TBL] [Abstract][Full Text] [Related]
9. Gram-Negative Skin and Soft Tissue Infections. Jabbour JF; Kanj SS Infect Dis Clin North Am; 2021 Mar; 35(1):157-167. PubMed ID: 33303333 [TBL] [Abstract][Full Text] [Related]
10. The role of multidrug and extensive-drug resistant Gam-negative bacteria in skin and soft tissue infections. Brink AJ; Richards GA Curr Opin Infect Dis; 2020 Apr; 33(2):93-100. PubMed ID: 31990811 [TBL] [Abstract][Full Text] [Related]
11. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Bader MS; Loeb M; Leto D; Brooks AA Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743 [TBL] [Abstract][Full Text] [Related]
12. [Susceptibilities of multidrug-resistant pathogens responsible for complicated skin and soft tissue infections to standard bacteriophage cocktails]. Gündoğdu A; Kılıç H; Ulu Kılıç A; Kutateladze M Mikrobiyol Bul; 2016 Apr; 50(2):215-23. PubMed ID: 27175494 [TBL] [Abstract][Full Text] [Related]
13. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. Falcone M; Paterson D J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599 [TBL] [Abstract][Full Text] [Related]
14. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms. Sharma R; Park TE; Moy S Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862 [TBL] [Abstract][Full Text] [Related]
15. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Liscio JL; Mahoney MV; Hirsch EB Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591 [TBL] [Abstract][Full Text] [Related]
17. Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria. Giacobbe DR; Mikulska M; Viscoli C Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1219-1236. PubMed ID: 30444147 [TBL] [Abstract][Full Text] [Related]
18. Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria. Jean SS; Liu IM; Hsieh PC; Kuo DH; Liu YL; Hsueh PR Int J Antimicrob Agents; 2023 May; 61(5):106763. PubMed ID: 36804370 [TBL] [Abstract][Full Text] [Related]
19. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations. Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276 [TBL] [Abstract][Full Text] [Related]
20. The role of Gram-negative bacteria in skin and soft tissue infections. Russo A; Trecarichi EM; Torti C Curr Opin Infect Dis; 2022 Apr; 35(2):95-102. PubMed ID: 34840273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]